Despite optimal surgery and appropriate first-line chemotherapy,∼ 70%–80% of patients
with epithelial ovarian cancer will develop disease relapse. The same modalities as used …

The natural history of ovarian cancer continues to be characterized by late-stage
presentation, metastatic bulky disease burden and stagnant mortality statistics, despite …

Background The benefits of secondary cytoreduction for platinum-sensitive relapsed ovarian
cancer are still widely debated. We aimed to assess the efficacy of secondary cytoreduction …

Background Secondary surgical cytoreduction in women with platinum-sensitive, recurrent
epithelial ovarian, primary peritoneal, or fallopian-tube (“ovarian”) cancer is widely practiced …

The estimated number of new ovarian cancer cases in Europe in 2012 was 65 538 with 42
704 deaths [1]. There is variation in the incidence rate across the continent with a higher …

Ovarian cancer (OC) is the fifth most common cause of cancer death in women. Although
significant progress has been made in the treatment of OC, the majority of patients …

Vascular endothelial growth factor (VEGF) is a key regulator of angiogenesis which drives
endothelial cell survival, proliferation, and migration while increasing vascular permeability …

Background Homologous recombination deficiency (HRD) is a molecular biomarker for
administrating PARP inhibitor (PARPi) or platinum-based (Pt) chemotherapy. The most well …

Background Ovarian cancer remains the most deadly gynecologic cancer with the majority
of patients relapsing within 3 years of diagnosis. Traditional treatment paradigms linked to …

Purpose The aim of this study was to help with the process of selecting patients with
advanced ovarian cancer to undergo cytoreductive surgery (CRS) with hyperthermic …